Pharmacokinetics, Excretion, and Mass Balance of [14 C]-Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men-Reference-Cited by-同舟云学术

Pharmacokinetics, Excretion, and Mass Balance of [14 C]-Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men

Published:2018-09-19 Issue:8 Volume:7 Page:901-910
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Ambery Claire¹,Young Graeme²,Fuller Teresa³,Lazaar Aili L.⁴,Pereira Adrian²,Hughes Adam²,Ramsay David⁵,van den Berg Frans⁶,Daley-Yates Peter⁷

Affiliation:

1. Clinical Pharmacology Modelling and Simulation; GSK; Stockley Park West Uxbridge Middlesex UK

2. Bioanalysis, Immunogenicity and Biomarkers (BIB); GSK; Ware Hertfordshire UK

3. GSK; Medicines Research Centre; Stevenage Hertfordshire UK

4. Respiratory Therapy Area Unit; GSK; R&D; King of Prussia PA USA

5. Quanticate Ltd.; Edinburgh UK

6. Hammersmith Medicines Research; London UK

7. Clinical Development; GSK; Research and Development; Uxbridge Middlesex UK

Funder

GlaxoSmithKline foundation

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpdd.616/fullpdf

Reference21 articles.

1. Global Initiative for Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for diagnosis, management and prevention of COPD http://www.goldcopd.org

2. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper;Celli;Eur Respir J,2004

3. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients;Cazzola;Respir Med,2005

4. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD;Cazzola;Pulm Pharmacol Ther,2010

5. Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and beta2-adrenoceptor agonist properties;Hegde;J Pharmacol Exp Ther,2014

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non‐Labeled, Stable Labeled, or Radiolabelled Approaches for Provision of Intravenous Pharmacokinetics in Humans: A Discussion Piece;Clinical Pharmacology & Therapeutics;2023-12-22

2. Investigation of the human metabolism and disposition of the prolyl hydrolase inhibitor daprodustat using IV microtracer with Entero‐Test bile string;Pharmacology Research & Perspectives;2023-10-26

3. Design, conduct, and interpretation of human mass balance studies and strategies for assessing metabolites-in-safety testing (MIST) in drug development;Overcoming Obstacles in Drug Discovery and Development;2023

4. Considerations for Human ADME Strategy and Design Paradigm Shift(s) – An Industry White Paper;Clinical Pharmacology & Therapeutics;2022-09-02

5. Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects;Drug Metabolism and Disposition;2021-12-01